4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aa,5a,6aa)-octahydro- 2-methylcyclopenta[c]pyrrol-5-yl]methoxy]- - Names and Identifiers
Name | N-(3,4-Dichloro-2-fluorophenyl)-6-methoxy-7-{[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy}-4-quinazolinamine
|
Synonyms | XL647 CS-197 xl 647 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aa,5a,6aa)-octahydro- 2-met N-(3,4-Dichloro-2-fluorophenyl)-6-methoxy-7-{[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy}-4-quinazolinamine N-(3,4-Dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aα,5α,6aα)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-4-quinazolinamine 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aα,5α,6aα)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy]- 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aa,5a,6aa)-octahydro- 2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-
|
CAS | 651031-01-5
|
InChI | InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13?,14-,15+ |
4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aa,5a,6aa)-octahydro- 2-methylcyclopenta[c]pyrrol-5-yl]methoxy]- - Physico-chemical Properties
Molecular Formula | C24H25Cl2FN4O2
|
Molar Mass | 491.39 |
Storage Condition | Room Temprature |
4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aa,5a,6aa)-octahydro- 2-methylcyclopenta[c]pyrrol-5-yl]methoxy]- - Introduction
-(3, 4-dichloro)-6-methoxy-7-{[(3aR,6aS)-N [c]pyrrol-5-yl]methoxy}-4-quazolinamine is a compound whose chemical name is N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-{[(3aR,6aS)-2-Methyloctylcyclopenta- [c]pyrrol-5-yl]methoxy}-4-quinazolinamine.
N-(,,)-6-methoxy-7-{[(3aR,6aS)-3 pyrrol-5-yl]methoxy}-4-quinazolinamine is a tyrosine kinase inhibitor used in the preparation of anticancer drugs. Tyrosine kinase is an important enzyme involved in cell signal transduction. Inhibition of tyrosine kinase can interfere with cell growth and division, so as to achieve the purpose of cancer treatment.
the preparation method of N-(,)-6-methoxy-7-{[(3aR,6aS)-3 [pyrrol-5-yl] 4-quinazolinamine] methoxy} generally involves a series of chemical reactions, including aniline reaction, chlorination reaction, formaldehyde condensation reaction, etc. Specific preparation procedures and conditions can be found in the relevant patent literature.
Safety information about N -3, ()-6-methoxy-7-{[(3aR,6aS)-[3aR] pyrrol-5-yl]methoxy-4-quinazolinine is required. As with all chemical substances, pay attention to safe operation. Appropriate laboratory practices and chemical safety guidelines should be followed. Hazard of N-(3,)-6-methoxy-7-{[(3aR,6aS)-[c]pyrrol-5-yl methoxy}-4-inazolinamine may be toxic to humans, potential needs to be evaluated and controlled. During use, wear appropriate protective equipment such as laboratory suits, gloves and goggles. At the same time, store N -3, +)-6-methoxy-7-{[(3aR,6aS)-[3aR]-pyrrol-5-yl]methoxy-4-quinazolinine in a dry, cool, and well-ventilated place to avoid reaction with oxidants and strong acids.
it should be noted that N-(3,)-6-methoxy-7-{[(3aR,6aS)-[c]pyrrol-5-yl]methoxy}-4-quinazolinamine, as a research compound, needs further research and evaluation in clinical practice, and has not been widely used in clinical treatment at present.
Last Update:2024-04-09 21:11:58